Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.
Latest full-year results from official filings.
Parent Danaher (DHR) group FY2025 revenue $24.57bn (+3.0%); operating margin 19.1%; net income $3.60bn.
Figures cover the whole listed group, not this business alone.
Credible news about incidents, disputes, legal action or restructuring in the last 24 months.
No adverse media involving Beckman Coulter found in HSH's search of the last 24 months.
Data breaches, cyber incidents, regulator action and assurance status.
Feb 2025: A medium-severity vulnerability (CVE-2025-0941) was published for Beckman Coulter Life Sciences' MET ONE 3400+ particle counter, which could store credentials in plain text in rare conditions. No breaches or regulator actions found. NHS DSPT status not yet checked.
Recalls, safety notices, regulator action and clinical safety concerns.
Mar 2026: The FDA posted a Class 2 recall of one lot of Beckman Coulter MicroScan Neg MIC 56 panels, started by the firm in Jul 2025, owing to likely contamination in a test well.
Contract delivery, go-lives, terminations and disputes.
Apr 2025: University Hospitals of North Midlands NHS Trust gave notice of a pathology managed service award to Beckman Coulter for its Leighton and Macclesfield sites; in Oct 2025 GOSH directly awarded it a £272k lab automation contract.